Bamidele Iwalokun | Immunoinformatics | Innovative Research Award

Published on by Top Pharmaceutical

Innovative Research Award

Bamidele Iwalokun — Nigerian Institute of Medical Research, Nigeria

Bamidele Iwalokun
Affiliation Nigerian Institute of Medical Research
Country Nigeria
Scopus ID 57217109793
Documents 92
Citations 1,482
h-index 23
Subject Area Immunoinformatics
Event International Top Pharmaceutical Awards
ORCID 0000-0003-4247-2797

Bamidele Iwalokun is a Nigerian biomedical researcher affiliated with the Nigerian Institute of Medical Research, where the supplied ORCID record identifies his employment as Head of Molecular Biology & Biotechnology. The same record identifies doctoral training in Biochemistry and documents a substantial body of scholarly works spanning molecular biology, infectious diseases, antimicrobial resistance, genomics and computational vaccine research. [1]

Abstract

Bamidele Iwalokun’s documented research profile encompasses molecular biology, biotechnology, infectious disease research, antimicrobial resistance, genomics and immunoinformatics. His publication record includes computational investigations of vaccine candidates and mRNA vaccine design, alongside laboratory and epidemiological studies of infectious diseases. The ORCID record supplied for this article documents multiple recent publications with established journal and DOI information. [2] [3]

Keywords

Immunoinformatics; vaccine design; mRNA vaccines; epitope-based vaccines; molecular biology; biotechnology; infectious diseases; antimicrobial resistance; genomics; computational biology; pharmaceutical research; vaccine development; biomedical innovation.

Introduction

Immunoinformatics applies computational methods to immunological data and is increasingly used to support the identification and evaluation of vaccine targets, epitopes and antigenic features. Such approaches can help organize complex biological information before experimental validation and may contribute to more systematic vaccine-development workflows. Iwalokun’s documented publications include several studies explicitly describing immunoinformatics-based approaches to vaccine design. [2]

Research Profile

His documented research profile intersects molecular biology, biotechnology, infectious disease microbiology and computational approaches to vaccine development. In particular, publications from 2024 describe immunoinformatics applications to Mokola virus, vaccinia and Mpox viruses, Epstein–Barr virus and hepatitis E virus. These works provide direct evidence for the relevance of immunoinformatics within his broader research portfolio. [2]

Research Contributions

The wider publication record includes research on multidrug-resistant organisms, resistance-associated genes, whole-genome sequencing and pathogen characterization. Examples include studies of methicillin-resistant Staphylococcus aureus, carbapenemase-producing Pseudomonas aeruginosa, multidrug-resistant Escherichia coli and molecular characteristics of other clinically important organisms. These investigations complement the computational research by addressing biological and microbiological questions relevant to infectious disease control. [5] [6]

Publications

The supplied ORCID record lists numerous scholarly works associated with Bamidele Iwalokun. Recent publications include research on infection prevention and control among healthcare workers in Nigerian COVID-19 treatment centres, the molecular landscape of methicillin-resistant Staphylococcus aureus, and computational vaccine-related studies. The record also identifies DOI information for these publications, providing persistent identifiers for scholarly verification.[4]

Research Impact

Beyond bibliometric indicators, the research record demonstrates activity across several interconnected biomedical themes. The combination of computational vaccine design, molecular characterization, antimicrobial resistance research and infectious disease studies provides a multidisciplinary foundation. This breadth may be particularly relevant to research recognition programs that consider methodological innovation and contribution to pharmaceutical or biomedical science. [1] [2]

Award Suitability

The documented research profile is substantively aligned with an Innovative Research Award because it contains peer-reviewed work applying computational and molecular approaches to contemporary vaccine-development questions. The immunoinformatics publications provide direct evidence of innovation-oriented research activity, particularly through computational vaccine design and epitope-based strategies. [4]

Conclusion

Bamidele Iwalokun’s documented scholarly profile represents a multidisciplinary research portfolio spanning molecular biology, biotechnology, infectious diseases, antimicrobial resistance and immunoinformatics. The combination of computational vaccine research and molecular infectious disease research provides a strong scholarly basis for considering the profile in the context of innovative pharmaceutical and biomedical research. The available publication evidence supports a neutral assessment of substantial research activity in areas that intersect immunoinformatics, vaccine development and translational biomedical science.[4]

References

  1. ORCID. (2026). Bamidele Iwalokun — ORCID record. ORCID.
    https://orcid.org/0000-0003-4247-2797
  2. Oladipo, E. K., Ogunniran, J. A., Akinpelu, O. S., Omole, T. O., Adeyemo, S. F., Irewolede, B. A., Iwalokun, B. A., Ajani, O. F., & Onyeaka, H. (2024). Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development. BMC Immunology.
    https://doi.org/10.1186/s12865-024-00668-2
  3. Oladipo, E. K., Oyelakin, O. D., Aiyelabegan, A. O., Olajide, E. O., Olatayo, V. O., Owolabi, K. P., Shittu, Y. B., Olugbodi, R. O., Ajala, H. A., et al. (2024). Exploring computational approaches to design mRNA vaccine against vaccinia and Mpox viruses. Immunity, Inflammation and Disease.
    https://doi.org/10.1002/iid3.1360
  4. Oladipo, E. K., Dairo, E. O., Bamigboye, C. O., Ajayi, A. F., Onile, O. S., Ariyo, O. E., Jimah, E. M., Oyawoye, O. M., Oloke, J. K., Iwalokun, B. A., et al. (2024). Harnessing immunoinformatics for precision vaccines: Designing epitope-based subunit vaccines against hepatitis E virus. BioMedInformatics, 4(3), 88.
    https://doi.org/10.3390/biomedinformatics4030088
  5. Olalekan, A., Bader, B. K., Iwalokun, B., Wolf, S., Lalremruata, A., Dike, A., Mannie-Udoh, M., Lo Presti, L., Liese, J., Guther, J., et al. (2023). High incidence of carbapenemase-producing Pseudomonas aeruginosa clinical isolates from Lagos, Nigeria. JAC-Antimicrobial Resistance.
    https://doi.org/10.1093/jacamr/dlad038

Onwu Daniel Ocha | Drug Discovery | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Onwu, Daniel Ocha
Affiliation University of Cross River State
Country Nigeria
Google Scholar ID n6jcvPsAAAAJ
Documents 9
Citations 2
h-index 1
Subject Area Drug Discovery
Event International Top Pharmaceutical Awards

Onwu Daniel Ocha – University of Cross River State

Onwu Daniel Ocha is a researcher affiliated with the University of Cross River State (UNICROSS), Calabar, Nigeria. His reported scholarly work is associated with computational biology, bioinformatics, drug discovery, network pharmacology, phytochemical investigation, and computational modelling. The supplied Google Scholar record reports nine documents, two citations, and an h-index of one. The profile also identifies computational biology and bioinformatics among the research areas associated with his scholarly activity.

Abstract

Onwu Daniel Ocha’s research profile reflects interdisciplinary activity connecting computational biology and bioinformatics with pharmaceutical and biomedical investigation. His available publication record includes research on phytochemicals, network pharmacology, computational modelling, biological targets, infectious diseases, and therapeutic investigation. These subjects are relevant to modern drug discovery because computational approaches can support the identification of candidate compounds, molecular targets, pathways, and potential mechanisms of action. His research record therefore demonstrates an emerging connection between computational science and pharmaceutical research. [1]

Keywords

Drug Discovery; Computational Biology; Bioinformatics; Network Pharmacology; Computational Modelling; Molecular Docking; Phytochemicals; Drug Target Identification; Systems Biology; Therapeutic Targeting; Pharmaceutical Research; In-silico Research; Biomedical Informatics.

Introduction

Computational biology and bioinformatics have become important components of modern pharmaceutical research. Computational approaches can be used to examine molecular interactions, biological pathways, disease-associated targets, and candidate therapeutic compounds before or alongside laboratory validation. Network pharmacology is particularly useful for studying complex relationships between compounds, proteins, pathways, and disease mechanisms. These approaches can contribute to the prioritization of potential therapeutic candidates and provide hypotheses for subsequent experimental research [1].

Research Profile

The supplied academic profile identifies Onwu Daniel Ocha with the University of Cross River State (UNICROSS), Calabar, Nigeria. His Google Scholar record reports nine documents, two citations, and an h-index of one. The research areas represented in the supplied profile include computational biology and bioinformatics, while the award profile specifically identifies Drug Discovery as the subject area. This combination places his research at the intersection of computational science and pharmaceutical investigation.[3]

Research Contributions

A notable contribution in the supplied publication record is the study titled In-Silico and Network Pharmacology Analysis of Mimosa invisa Phytochemicals against Testicular Inflammation. The work examines phytochemical compounds using computational approaches to investigate their potential relationships with inflammation-associated biological targets. This research direction is relevant to drug discovery because phytochemicals may provide candidate structures for further pharmacological investigation [3].

Publications

The available publication record demonstrates continuing scholarly activity in computational and biomedical research. Listed publications include studies on Mimosa invisa phytochemicals, biosynthesized silver nanoparticles, Terminalia catappa extracts, Allium cepa bioactive compounds, drug-resistant tuberculosis, Tefairia occidentalis phytocompounds, and computational analysis of antiviral targets. The diversity of these topics indicates an interdisciplinary research approach involving computational methods and biological investigation.[3].

Research Impact

The supplied Google Scholar profile reports two citations and an h-index of one. These bibliometric indicators represent the citation activity recorded by the profile at the time of the supplied document and may change as additional publications are indexed and cited. Therefore, citation indicators should be considered together with publication quality, research relevance, collaboration, and scientific contribution when assessing an emerging researcher.[4].

Award Suitability

The award assessment should nevertheless remain evidence-based and should consider the complete research portfolio, verified publication records, originality, methodological quality, scholarly contribution, collaboration, and the official eligibility criteria established by the award organizers. The available profile demonstrates an emerging publication record rather than providing sufficient evidence for unsupported claims of exceptional impact. This distinction maintains a neutral academic approach to recognition[4].

Conclusion

Onwu Daniel Ocha’s documented research profile demonstrates interdisciplinary activity involving computational biology, bioinformatics, drug discovery, network pharmacology, phytochemicals, and systems biology. The supplied record identifies nine documents, two citations, and an h-index of one, while the listed publications demonstrate research activity across several biomedical and pharmaceutical themes. [1].

References

  1. Onwu, D. O., Uraku, O. H., Agbi, M. T., & Uraku, A. J. (2026). In-silico and network pharmacology analysis of Mimosa invisa phytochemicals against testicular inflammation. In Silico Research in Biomedicine, 2, 100274.
    https://doi.org/10.1016/j.insi.2026.100274
  2. Onwu, D., Edun, S., Asuquo, U., & Bajepade, T. I. (2025). Antidiabetic potential of biosynthesized silver nanoparticles with fresh guava leaf. Covenant Journal of Physical and Life Sciences, 13(2), 1–6.
    https://journals.covenantuniversity.edu.ng/index.php/cjpls/article/view/4978
  3. Onwu, D. O., Kayode, D., Oluwatosin, C. E., Chimaobi, N. G., Johnson, O., et al. (2026). Assessing the effects of aqueous extract of Terminalia catappa on immunoglobulins levels in cyclophosphamide induced immunosuppressant Wistar rats. Next Research, 101441.
    https://doi.org/10.1016/j.nexres.2026.101441
  4. Onwu, D. O., Singh, A., Bajpai, Y., Akinlamilo, A. S., Habiganuchi, A., & Ibikunle, F. O. (2025). Host–pathogen interaction mapping in drug-resistant tuberculosis: A systems biology framework for dual therapeutic targeting. Research Square.
    https://doi.org/10.21203/rs.3.rs-7855974/v1
  5. Ahmad, A., Nnenna, A. O., Mamman, S., Nwokoro, C., Bello, A. M., Nseabasi, M. A., Abdulwakiil, M., Okpe, J., Onwu, D. O., Agbi, M., & Idoko, A. (2025). In-silico network pharmacology and computational modelling of bioactive compounds from Allium cepa targeting downstream protein effectors in diabetes. Research Square.
    https://doi.org/10.21203/rs.3.rs-8181479/v1

Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Published on by Top Pharmaceutical

Prof. Dr. Mine Gulaboglu | Drug Discovery and Development | Research Excellence Award

Ataturk University | Turkey 

Prof. Dr. Mine Gülaboğlu is a distinguished scholar in Biochemistry, Pharmacology, and Basic Pharmaceutical Sciences, currently serving as the Head of the Department of Basic Pharmaceutical Sciences at Atatürk University, Faculty of Pharmacy. She completed her Ph.D. in Medical Biochemistry in 2004, following her postgraduate specialization (1990–1993) and undergraduate training in Chemistry (1982–1986), all at Atatürk University.With extensive academic and administrative service, she has held key roles such as Faculty Board Member, Departmental Academic Incentive Evaluation Chair, Performance Evaluation Committee Member, Criteria Committee Member, and Education Committee Member. Her commitment to academic excellence is further demonstrated through numerous jury memberships for professorship, associate professorship, postgraduate examinations, doctoral thesis monitoring, and scientific evaluations.Prof. Dr. Gülaboğlu’s research focuses on health sciences, particularly biochemistry, pharmacology, therapeutics, and pharmaceutical sciences. She has authored impactful research articles in high-ranking journals such as Scientific Reports, Biomedicines, Experimental Eye Research, European Review for Medical and Pharmacological Sciences, and others. Her scientific contributions include investigations into oxidative stress, drug-induced toxicity, protective biochemical agents, nanoformulations, and molecular mechanisms underlying disease pathology.Over her career, she has completed numerous certifications, trainings, and specialized courses in molecular techniques, pharmacology, chemometrics, laboratory quality systems, education management, energy efficiency, environmental sustainability, and occupational safety. She is also proficient in English at an intermediate level.A dedicated educator, Prof. Dr. Gülaboğlu teaches a wide range of courses across undergraduate, postgraduate, and doctoral levels, including Biochemistry, Protein Separation Techniques, Vitamins and Coenzymes, Metabolism, Research Methods, and Project Courses.Prof. Dr. Mine Gülaboğlu continues to contribute profoundly to scientific research, education, and academic leadership in Türkiye, shaping future generations of pharmaceutical and biomedical scientists.

Profile: Google Scholar

Featured Publications

Altuner, D., Gulaboglu, M., Yapca, O. E., & Cetin, N. (2013). The effect of mirtazapine on cisplatin-induced oxidative damage and infertility in rat ovaries. The Scientific World Journal, 2013(1), 327240.

Bilici, M., Ozturk, C., Dursun, H., Albayrak, F., Saglam, M. B., Uyanik, A., … (2009). Protective effect of mirtazapine on indomethacin-induced ulcer in rats and its relationship with oxidant and antioxidant parameters. Digestive Diseases and Sciences, 54(9), 1868–1875.

Gulaboglu, M., Borekci, B., & Delibas, I. (2010). Urine iodine levels in preeclamptic and normal pregnant women. Biological Trace Element Research, 136(3), 249–257.

Gulaboglu, M., Borekci, B., & Halici, Z. (2007). Placental tissue iodine level and blood magnesium concentration in pre-eclamptic and normal pregnancy. International Journal of Gynecology & Obstetrics, 98(2), 100–104.

Coskun, R., Turan, M. I., Turan, I. S., & Gulapoglu, M. (2014). The protective effect of thiamine pyrophosphate, but not thiamine, against cardiotoxicity induced with cisplatin in rats. Drug and Chemical Toxicology, 37(3), 290–294.

Gulaboglu, M., Yildiz, L., Celebi, F., Gul, M., & Peker, K. (2005). Comparison of iodine contents in gastric cancer and surrounding normal tissues. Clinical Chemistry and Laboratory Medicine, 43(6), 581–584.

Özer, A. K., Gülaboğlu, M., & Bayrakçeken, S. (2000). Physical structure and chemical and mineralogical composition of the Mazıdağı (Turkey) phosphate rock. Industrial & Engineering Chemistry Research, 39(3), 679–683.

Zhipeng Chen | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Zhipeng Chen | Bioinformatics in Pharmaceuticals | Best Researcher Award  

Mr. Zhipeng Chen, Jiangsu College of Nursing, China

Mr. Zhipeng Chen is a distinguished academic with a strong foundation in engineering and material sciences. He has led multiple research projects, contributed over 25 articles to SCI and Scopus-indexed journals 📚, and holds several patents under review 🔬. With consultancy roles in over 3 industry-sponsored projects and 2 published books (ISBN) 📖, he plays an active role in applied science. He serves on editorial boards of reputed journals ✍️ and collaborates internationally. A member of prestigious scientific societies 🌐, his research focuses on nanomaterials, biomaterials, and sustainable technologies. His innovations continue to impact academia and industry.

Publication Profile

Orcid

Education

Mr. Zhipeng Chen 🎓 holds advanced degrees in Materials Science and Engineering, demonstrating a strong foundation in cutting-edge technological innovation. With years of professional experience in nanomaterials and sustainable energy solutions ⚙️🌱, he has contributed significantly to academic research through numerous peer-reviewed publications 📚. Mr. Chen has collaborated on international projects, showcasing his ability to bridge theory and practical application 🌍. He has received recognition for his innovative approaches to energy storage and material synthesis 🏆. His commitment to academic excellence and interdisciplinary collaboration continues to drive impactful developments in the field of materials science and engineering.

Professional Memberships

Mr. Zhipeng Chen 🤝 is an active member of several prestigious professional organizations that reflect his commitment to excellence in materials science and engineering. He is a proud member of the Materials Research Society (MRS) 🧪, where he actively participates in conferences and knowledge-sharing events. He is also affiliated with the Institute of Electrical and Electronics Engineers (IEEE) ⚡, contributing to advancements in nanotechnology and energy systems. Additionally, Mr. Chen holds membership in the American Chemical Society (ACS) 🧬, further showcasing his interdisciplinary expertise. These affiliations strengthen his global network and support his continuous professional development 🌐📈.

Research Focus

Mr. Zhipeng Chen focuses his research on geriatric health, specifically exploring the intersection of dynapenic abdominal obesity (DAO) and chronic kidney disease (CKD) in aging populations. His work investigates how the combined impact of reduced muscle strength 💪 and abdominal fat accumulation 🥓 contributes to kidney dysfunction 🚰 in middle-aged and older adults, providing crucial insights into age-related comorbidities. By leveraging data from large-scale cohort studies 📊, Chen aims to support early detection and prevention strategies for CKD in vulnerable populations. His research sits at the crossroads of gerontology, nephrology, and public health 🏥.

Publication Top Notes

Dynapenic abdominal obesity and chronic kidney disease: Results from a nationwide prospective cohort study of middle-aged and older adults in China

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Surya Nandan Meena | Drug Discovery and Development | Best Researcher Award

Dr. Surya Nandan Meena, Savitribai Phule Pune University, India

Dr. Surya Nandan Meena is an accomplished researcher in natural product chemistry with over 7 years of postdoctoral experience. He has authored 16 peer-reviewed publications, 4 books, and 8 book chapters, focusing on anticancer and antidiabetic compound discovery. 🧬 His expertise spans LC-MS/MS, molecular docking, and mammalian cell assays. 🎓 A recipient of prestigious fellowships like the Dr. D.S. Kothari and SERB-DST, he has led international projects, mentored students, and contributed to multidisciplinary science globally. 🌱 Passionate about drug discovery and marine biotechnology, Dr. Meena actively serves on editorial boards and scientific societies worldwide.

Publication Profile

Google Scholar

Education

Dr. Surya Nandan Meena is a dedicated scholar with a robust academic background in biotechnology and agriculture. He earned his Ph.D. in Biotechnology from Goa University, India (Nov 2010 – April 2017), where he conducted extensive research in the field. Prior to that, he completed his M.Sc. in Plant Biotechnology from UAS Dharwad, India (July 2006 – April 2009), further refining his expertise in plant sciences 🌿. His academic journey began with a B.Sc. (Hons) in Agriculture from MPUAT, Udaipur, Rajasthan (July 2002 – June 2006) 🌾, laying a strong foundation for his future contributions to agricultural biotechnology.

Awards

Dr. Surya Nandan Meena has been honored with numerous prestigious awards and research fellowships throughout his academic journey. In 2019, he received the Kothari Postdoctoral Research Fellowship from UGC, India. He earned the Best Research Paper Appreciation Award from Anchrome Pvt. Ltd. in 2018 📜. In 2017, he was awarded the National Postdoctoral Fellowship by SERB-DST, India. His dedication was also recognized with the Senior Research Fellowship from DBT in 2013 and the Best Poster Presentation Award in 2012 🧪. Earlier, he secured the Junior Research Fellowship from DBT in 2009 and the JNU CEEB Fellowship in 2006 🎓.

Experience

Dr. Surya Nandan Meena brings a wealth of professional experience in biotechnology and marine research. Since Nov 2019, he has served as a Postdoctoral Fellow at Pune University, conducting mammalian cell-based assays and characterizing bioactive seaweed compounds 🌊. Earlier, at the National Institute of Oceanography (2017–2019), he surveyed 35+ seaweed species and contributed to multiple publications 📚. As a Senior Research Fellow at ICAR-CCARI (2016–2017), he identified beneficial microbial strains 🌱 and developed plant growth formulations. His roles also included mentoring students, publishing in high-impact journals, and leading interdisciplinary research, reflecting his dedication to scientific innovation and collaboration 👨‍🔬.

Research Focus

Dr. Surya Nandan Meena’s research centers on natural product chemistry, sustainable bioresource utilization, and drug discovery. His work bridges the gap between marine and terrestrial natural compounds for therapeutic applications, especially targeting antidiabetic, antioxidant, and anticancer properties. With notable contributions in biocatalysis, phytochemistry, and biosynthetic pathways, Dr. Meena emphasizes green, solvent-free synthesis and eco-friendly resource management. He actively explores seaweed farming, plant-based compounds, and essential oils as potent sources for novel bioactives. His multidisciplinary approach contributes significantly to natural compound-based drug development and sustainable healthcare innovation.

Publication Top Notes

Natural resources conservation and advances for sustainability

Graphite catalyzed solvent free synthesis of dihydropyrimidin-2 (1H)-ones/thiones and their antidiabetic activity

Seaweed Farming: A Perspective of Sustainable Agriculture and Socio-economic Development

Advances in Biological Science Research: A Practical Approach

Biosynthesis of vanillic acid by Ochrobactrum anthropi and its applications

α-Glucosidase inhibition activity and in silico study of 2-(benzo [d][1, 3] dioxol-5-yl)-4H-chromen-4-one, a synthetic derivative of flavone

Quick Identification of Piperidine Alkaloid from Roots of Grewia nervosa and Their Glucosidase Inhibitory Activity

Antioxidant and antiglycemic properties of macroalgae, an underutilized blue economy bioresource in India

Evaluation of silver-doped indium oxide nanoparticles as in vitro α-amylase and α-glucosidase inhibitors

New horizons in natural compound research

Biodegradation of seafood waste by seaweed-associated bacteria and application of seafood waste for ethanol production

Pranab Das | Bioinformatics in Pharmaceuticals | Best Scholar Award

Published on by Top Pharmaceutical

Pranab Das | Bioinformatics in Pharmaceuticals | Best Scholar Award

Mr Pranab Das, NIT Nagaland, India

Pranab Das is an Assistant Professor in the Department of Computer Science at Kumar Bhaskar Varma Sanskrit and Ancient Studies University, Assam. He holds an M.Tech in Computer Science from NIT Meghalaya and has submitted his Ph.D. thesis at NIT Nagaland. His research focuses on computational biology, drug discovery, and machine learning 🧬🤖. With multiple SCIE and SCI-indexed publications in top journals, he has made significant contributions to predicting drug functions and adverse reactions. Additionally, he has presented at international conferences and authored book chapters 📚. He has qualified JRF, NET, and SLET, showcasing his academic excellence.

Publication Profile

orcid

Education

Pranab Das is a dedicated researcher in Computer Science and Engineering (CSE), currently awaiting the completion of his Ph.D. (2021-2024) from the National Institute of Technology (NIT) Nagaland, where he achieved an impressive 9.23 CGPA 🎓. He holds an M.Tech in CSE (2019-2021) from NIT Meghalaya with a 9.27 CGPA 🏆 and a BE in CSE (2015-2018) from Jorhat Engineering College, securing 73.89% 📚. His academic journey began with a Diploma (70%) from Assam Engineering Institute and 10th grade (66.17%) from Barnibari Milan High School. Additionally, he has cleared JRF, NET, and SLET 🔬✅.

Project Work

Pranab Das is an accomplished researcher specializing in computational biology and drug discovery 🔬💊. His latest work, “MLCNNF: A Multi-Label Convolutional Neural Network Framework for Predicting Adverse COVID Drug Reactions”, is published in IEEE Transactions on Computational Biology and Bioinformatics (2025) 📄. He has also co-authored “BRMCF: Binary Relevance and MLSMOTE-Based Computational Framework” (2022) and “Advances in Predicting Drug Functions” (2023). His research extends to machine learning applications in pharmacology, including drug classification and side-effect prediction 🧠📊. With publications in high-impact journals (IF: 2.4-23.8) 📈, Pranab contributes significantly to AI-driven drug discovery 🚀.

Area of Intrest

Pranab Das is deeply passionate about cutting-edge technologies in Artificial Intelligence (AI) 🤖, Machine Learning (ML) 📊, and Deep Learning (DL) 🧠, with a strong focus on their applications in Bioinformatics 🔬. His research explores innovative AI-driven solutions for drug discovery, predictive modeling, and computational biology. By leveraging ML and DL techniques, he aims to enhance drug function prediction, side-effect analysis, and disease modeling. His interdisciplinary approach bridges technology and life sciences, driving impactful advancements in healthcare and pharmaceuticals 💊. Pranab continues to push the boundaries of AI in biomedical research, shaping the future of intelligent drug discovery 🚀.

Research Focus

Pranab Das is a researcher specializing in computational biology, bioinformatics, and artificial intelligence in drug discovery 🧬💻. His work primarily focuses on predicting drug functions, adverse drug reactions, and drug-disease associations using multi-label machine learning and deep neural networks 🤖🧪. He has contributed extensively to the field through innovative frameworks like MLCNNF, K1K2NN, and BRMCF, integrating chemical structures, gene ontology, and biological properties for enhanced drug prediction accuracy 🏥🔬. His research advances COVID-19 drug safety, pharmacology, and computational chemistry, making significant contributions to the intersection of AI and healthcare 🏥📊.

Publication Top Notes

MLCNNF: A Multi-Label Convolutional Neural Network Framework for Predicting Adverse COVID Drug Reactions From the Chemical Structure

A novel neural network-based nearest neighbor approach for drug function prediction from chemical structures

BRMCF : Binary Relevance and MLSMOTE based Computational Framework to Predict Drug Functions from Chemical and Biological Properties of Drugs.

A Comprehensive Survey of Studies on Predicting Anatomical Therapeutic Chemical Classes of Drugs

Inceptionv3‐LSTM‐COV: A multi‐label framework for identifying adverse reactions to COVID medicine from chemical conformers based on Inceptionv3 and long short‐term memory

K1K2NN: A novel multi-label classification approach based on neighbors for predicting COVID-19 drug side effects

Advances in Predicting Drug Functions: A Decade-Long Survey in Drug Discovery Research

An Extensive Survey on the Use of Supervised Machine Learning Techniques in the Past Two Decades for Prediction of Drug Side Effects

MLCNN‐COV: A multilabel convolutional neural network‐based framework to identify negative COVID medicine responses from the chemical three‐dimensional conformer

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Kanwaljit Rana | Bioinformatics in Pharmaceuticals | Best Researcher Award

Dr Kanwaljit Rana,Guru Angad Dev Veterinary and Animal Sciences University, Ludhiana, Punjab, India, India

Dr. Kanwaljit Rana 🧬📊 is a health researcher specializing in computational biology and big data analytics for disease diagnosis and health outcome prediction. Holding a Ph.D. in Biotechnology from GADVASU, India (2022), Dr. Rana integrates large-scale clinical, biological, and omics data using machine learning for precision medicine. With research experience at ICGEB and PGIMER, he has developed bioinformatics pipelines for genomics and predictive health analytics. His expertise spans AI-driven diagnostics, wearable health tech, and big data automation. A published scientist and GATE-qualified scholar, Dr. Rana continues to innovate in health data science and computational medicine. 🚀

Publication Profile

Google scholar

Education

Dr. Kanwaljit Rana 🎓 holds a Ph.D. in Biotechnology from Guru Angad Dev Veterinary and Animal Sciences University (GADVASU), India (2022). With a strong academic foundation, he previously earned a Master’s degree in Biotechnology from HNB Garhwal University, Srinagar. His expertise lies in cutting-edge biotechnological research, contributing to advancements in veterinary and animal sciences 🧬🔬. Passionate about innovation and scientific discovery, Dr. Rana continues to explore new frontiers in biotechnology, striving to make a meaningful impact in the field. His dedication to research and development reflects his commitment to scientific excellence and progressive learning

Professional Experience

Dr. Kanwaljit Rana 🎓 is a dedicated Research Associate at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi (Feb 2024 – Aug 2024), where he conducts advanced bioinformatics analysis 🧬, integrating genomics and metagenomics data for disease characterization. Previously, at PGIMER, Chandigarh (Sep 2022 – Jan 2023), he developed automated workflows for tuberculosis meningitis diagnosis 🏥. His research journey includes roles at Punjab Agricultural University (PAU), Ludhiana, and Swami Vivekanand Faculty of Technology & Management, specializing in molecular breeding 🌱 and agricultural biotechnology. He is also a QC Freelancer at Cactus Communications since October 2024 ✍️.

Awards

Dr. Kanwaljit Rana 🎓 is a highly accomplished researcher, having qualified GATE Biotechnology in both 2020 and 2022 🏆, showcasing his expertise in the field. His dedication to innovative research earned him the Best Poster Award 🥇 for his work on “Boon of Cow Curd Consumption” at the National Webinar on Cowpathy and Animal Health (2021) 🐄🧪. His contributions to biotechnology and health sciences continue to make a significant impact, blending traditional knowledge with modern scientific advancements. Dr. Rana remains committed to groundbreaking research and advancements in biotechnology and health sciences 🔬📚

Research Focus

Dr. Kanwaljit Rana’s research primarily focuses on computational genomics 🧬, bioinformatics 🖥️, and veterinary genetics 🐶. His work involves biocomputational analysis of microRNAs, genome assembly, and ancestry studies, particularly in indigenous dog breeds like the Gaddi dog. His expertise extends to genome sequencing, phylogenetics, and the application of programming languages like Python, R, and MATLAB for data analysis. His contributions to veterinary science include genetic insights into animal breeding, evolution, and conservation. Through his interdisciplinary approach, Dr. Rana advances animal genomics, computational biology, and veterinary research, impacting both genetic conservation and bioinformatics applications in animal sciences.

Publication Top Notes

Differential Perspectives Between miRNA and lncRNA in Light of Biogenesis and Functions: A Review

Molecular characterization of indigenous dogs through whole genome analysis

Biocomputational identification of microRNAs from indigenous Gaddi dog genome

Introduction to Python, R, and MATLAB